<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h1>
      <div class="meta">2025-09-08 15:00:00+00:00 UTC</div>
      <ul>
        <li>2021 Jan 14;7(1):3.</li>
        <li>Sci Rep 15, 23495 (2025).</li>
        <li>2014 Oct 21;121(5):664–672.</li>
        <li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li>
        <li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li>
        <li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li>
        <li>doi: 10.1038/s41572-020-00235-0.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=First+Disclosure+of+Global+Interim+Phase+2+Data+for+BioNTech+and+Bristol+Myers+Squibb+PD-L1xVEGF-A+Bispecific+Antibody+Pumitamig+%28BNT327%2FBMS986545%29+in+Patients+with+Extensive-Stage+Small+Cell+Lung+Cancer+Shows+Encouraging+Antitumor+Activity%0A%E2%80%A2+2021+Jan+14%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fnews%2Ffirst-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
